C
Charles Willis Lugar
Researcher at Eli Lilly and Company
Publications - 22
Citations - 483
Charles Willis Lugar is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Estrogen receptor & Estrogen receptor beta. The author has an hindex of 12, co-authored 22 publications receiving 462 citations.
Papers
More filters
Journal ArticleDOI
Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia.
Bryan H. Norman,Jeffrey Alan Dodge,Timothy Ivo Richardson,Peter Stanley Borromeo,Charles Willis Lugar,Scott Alan Jones,Keyue Chen,Yong Wang,Gregory L. Durst,Robert J. Barr,Chahrzad Montrose-Rafizadeh,Harold E. Osborne,Robert M. Amos,Sherry Guo,and Amechand Boodhoo,Venkatesh Krishnan +15 more
TL;DR: SERBA-1 in vivo demonstrates involution of the ventral prostate in CD-1 mice (ERβ effect), while having no effect on gonadal hormone levels (ERα effect) at 10× the efficacious dose, consistent with in vitro properties of this molecule.
Journal ArticleDOI
Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity.
Jeffrey Alan Dodge,Charles Willis Lugar,Stephen Sung Yong Cho,Lorri L. Short,Masahiko Sato,Na N. Yang,Larry A. Spangle,Martin Michael John,David Lynn Phillips,Andrew L. Glasebrook,John J. Osborne,Charles A. Frolik,Henry Uhlman Bryant +12 more
TL;DR: Tissue distribution studies with radiolabelled metabolite indicate that conversion to raloxifene occurs readily in a variety of tissues including the liver, lung, spleen, kidney, bone and uterus, indicating that the origin of ral oxifene's pharmacology does not result from tissue-selective deconjugation of metabolite to parent.
PatentDOI
Growth hormone secretagogues
TL;DR: In this paper, the authors present novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal, as well as novel intermediates for use in the synthesis of said compounds, and novel processes employed in these syntheses.
Journal ArticleDOI
Structure−Activity Studies of 6-(Tetrazolylalkyl)-Substituted Decahydroisoquinoline-3-carboxylic Acid AMPA Receptor Antagonists. 1. Effects of Stereochemistry, Chain Length, and Chain Substitution
Paul L. Ornstein,Macklin Brian Arnold,N. K. Allen,Thomas J. Bleisch,Peter Stanley Borromeo,Charles Willis Lugar,J. D. Leander,David Lodge,D D Schoepp +8 more
TL;DR: The findings revealed that the optimal stereochemical array was the same for both NMDA (32 and 61) and AMPA (9) antagonists identified in this series and that the tetrahydroisoquinoline (25) and the C-1 carboxy (30) analogs of 9 are inactive.
Journal ArticleDOI
Novel 3-Aryl Indoles as Progesterone Receptor Antagonists for Uterine Fibroids
Timothy Ivo Richardson,Christian Alexander Clarke,Yu Kuo-Long,Ying K. Yee,Thomas J. Bleisch,Jose Eduardo Lopez,Scott Alan Jones,Norman Earle Hughes,Brian Stephen Muehl,Charles Willis Lugar,Terry L. Moore,Pamela K. Shetler,Richard W. Zink,John J. Osborne,Chahrzad Montrose-Rafizadeh,Nita J. Patel,Andrew G. Geiser,Rachelle J. Sells Galvin,Jeffrey Alan Dodge +18 more
TL;DR: Novel 3-aryl indoles are reported as potent and efficacious progesterone receptor (PR) antagonists with potential for the treatment of uterine fibroids and demonstrated excellent selectivity over other steroid nuclear hormone receptors such as the mineralocorticoid receptors.